Gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
vinorelbine	vinorelbine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
nonsmall	nonsmall	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
lung	lung	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
age	age	O	O	O	O
70	70	O	O	O	O
years	years	O	O	O	O
or	or	O	O	O	O
older	older	O	O	O	O
or	or	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
can	can	O	O	O	O
not	not	O	O	O	O
receive	receive	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Oncopaz	oncopaz	O	O	O	O
Cooperative	cooperative	O	O	O	O
Group	group	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Although	although	O	O	O	O
the	the	O	O	O	O
prevalence	prevalence	O	O	O	O
of	of	O	O	O	O
nonsmall	nonsmall	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
lung	lung	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
high	high	O	O	O	O
among	among	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
few	few	O	O	O	O
data	data	O	O	O	O
are	are	O	O	O	O
available	available	O	O	O	O
regarding	regarding	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
group	group	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Recent	recent	O	O	O	O
reports	reports	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
single	single	O	O	O	O
agent	agent	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
vinorelbine	vinorelbine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
or	or	O	O	O	O
gemcitabine	gemcitabine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
GEM	gem	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
may	may	O	O	O	O
obtain	obtain	O	O	O	O
a	a	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
20	20	O	O	O	O
-	-	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
in	in	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
acceptable	acceptable	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
improvement	improvement	O	O	O	O
in	in	O	O	O	O
symptoms	symptoms	O	O	O	O
and	and	O	O	O	O
quality	quality	O	O	O	O
of	of	O	O	O	O
life	life	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
current	current	O	O	O	O
study	study	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
GEM	gem	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
or	or	O	O	O	O
those	those	O	O	O	O
with	with	O	O	O	O
some	some	O	O	O	O
contraindication	contraindication	O	O	O	O
to	to	O	O	O	O
receiving	receiving	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
assessed	assessed	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Forty-nine	forty-nine	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
were	were	O	O	O	O
included	included	O	O	O	O
,	,	O	O	O	O
38	38	O	O	O	O
of	of	O	O	O	O
whom	whom	O	O	O	O
were	were	O	O	O	O
age	age	O	O	O	O
>	>	O	O	O	O
/=	/=	O	O	O	O
70	70	O	O	O	O
years	years	O	O	O	O
and	and	O	O	O	O
11	11	O	O	O	O
were	were	O	O	O	O
age	age	O	O	O	O
<	<	O	O	O	O
70	70	O	O	O	O
years	years	O	O	O	O
but	but	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
some	some	O	O	O	O
contraindication	contraindication	O	O	O	O
to	to	O	O	O	O
receiving	receiving	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
evaluable	evaluable	O	O	O	O
for	for	O	O	O	O
response	response	O	O	O	O
and	and	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
was	was	O	O	O	O
comprised	comprised	O	O	O	O
of	of	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
25	25	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
plus	plus	O	O	O	O
GEM	gem	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
1000	1000	O	O	O	O
mg/m(2	mg/m(2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
on	on	O	O	O	O
Days	days	O	O	O	O
1	1	O	O	O	O
,	,	O	O	O	O
8	8	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
15	15	O	O	O	O
every	every	O	O	O	O
28	28	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
received	received	O	O	O	O
a	a	O	O	O	O
minimum	minimum	O	O	O	O
of	of	O	O	O	O
three	three	O	O	O	O
courses	courses	O	O	O	O
unless	unless	O	O	O	O
progressive	progressive	O	O	O	O
disease	disease	O	O	O	O
was	was	O	O	O	O
detected	detected	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
One	one	O	O	O	O
hundred	hundred	O	O	O	O
sixty-five	sixty-five	O	O	O	O
courses	courses	O	O	O	O
were	were	O	O	O	O
administered	administered	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
of	of	O	O	O	O
3	3	O	O	O	O
.	.	O	O	O	O

6	6	O	O	O	O
courses	courses	O	O	O	O
per	per	O	O	O	O
patient	patient	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
overall	overall	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
was	was	O	O	O	O
26	26	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
,	,	O	O	O	O
15	15	O	O	O	O
-	-	O	O	O	O
41	41	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Two	two	O	O	O	O
patients	patients	O	O	O	O
attained	attained	O	O	O	O
a	a	O	O	O	O
complete	complete	O	O	O	O
response	response	O	O	O	O
(	(	O	O	O	O
4	4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
11	11	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
22	22	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
achieved	achieved	O	O	O	O
a	a	O	O	O	O
partial	partial	O	O	O	O
response	response	O	O	O	O
.	.	O	O	O	O

Eastern	eastern	O	O	O	O
Cooperative	cooperative	O	O	O	O
Oncology	oncology	O	O	O	O
Group	group	O	O	O	O
performance	performance	O	O	O	O
status	status	O	O	O	O
improved	improved	O	O	O	O
in	in	O	O	O	O
35	35	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
those	those	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
initial	initial	O	O	O	O
value	value	O	O	O	O
>	>	O	O	O	O
0	0	O	O	O	O
,	,	O	O	O	O
whereas	whereas	O	O	O	O
relief	relief	O	O	O	O
of	of	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
1	1	O	O	O	O
symptom	symptom	O	O	O	O
without	without	O	O	O	O
worsening	worsening	O	O	O	O
of	of	O	O	O	O
other	other	O	O	O	O
symptoms	symptoms	O	O	O	O
was	was	O	O	O	O
noted	noted	O	O	O	O
in	in	O	O	O	O
27	27	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
55	55	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
median	median	O	O	O	O
time	time	O	O	O	O
to	to	O	O	O	O
progression	progression	O	O	O	O
was	was	O	O	O	O
16	16	O	O	O	O
weeks	weeks	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
1-year	1-year	O	O	O	O
survival	survival	O	O	O	O
rate	rate	O	O	O	O
was	was	O	O	O	O
33	33	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O
Toxicity	toxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
mild	mild	O	O	O	O
.	.	O	O	O	O

Six	six	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
12	12	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
World	world	O	O	O	O
Health	health	O	O	O	O
Organization	organization	O	O	O	O
Grade	grade	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
4	4	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
2	2	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
4	4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
Grade	grade	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
4	4	O	O	O	O
thrombocytopenia	thrombocytopenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
2	2	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
4	4	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
had	had	O	O	O	O
Grade	grade	O	O	O	O
3	3	O	O	O	O
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Three	three	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
severe	severe	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
6	6	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
died	died	O	O	O	O
of	of	O	O	O	O
sepsis	sepsis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
median	median	O	O	O	O
age	age	O	O	O	O
of	of	O	O	O	O
those	those	O	O	O	O
patients	patients	O	O	O	O
developing	developing	O	O	O	O
Grade	grade	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
4	4	O	O	O	O
neutropenia	neutropenia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
remaining	remaining	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
75	75	O	O	O	O
years	years	O	O	O	O
vs.	vs.	O	O	O	O
72	72	O	O	O	O
years	years	O	O	O	O
;	;	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.047	0.047	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
GEM	gem	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
moderately	moderately	O	O	O	O
active	active	O	O	O	O
and	and	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
except	except	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
age	age	O	O	O	O
>	>	O	O	O	O
/=	/=	O	O	O	O
75	75	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
age	age	O	O	O	O
group	group	O	O	O	O
had	had	O	O	O	O
an	an	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Therefore	therefore	O	O	O	O
the	the	O	O	O	O
prophylactic	prophylactic	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
granulocyte-colony	granulocyte-colony	O	O	O	O
stimulating	stimulating	O	O	O	O
factor	factor	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
considered	considered	O	O	O	O
with	with	O	O	O	O
this	this	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

New	new	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
combinations	combinations	O	O	O	O
with	with	O	O	O	O
higher	higher	O	O	O	O
activity	activity	O	O	O	O
and	and	O	O	O	O
lower	lower	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
are	are	O	O	O	O
needed	needed	O	O	O	O
for	for	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
advanced	advanced	O	O	O	O
NSCLC	nsclc	O	DISEASE	OTHERS	I
.	.	O	O	O	O

